Detalhe da pesquisa
1.
Blockade of IL-1α and IL-1ß signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy.
Cancer Immunol Immunother
; 72(3): 667-678, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36036818
2.
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Cancer Immunol Immunother
; 70(12): 3629-3642, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33948686
3.
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.
Int J Cancer
; 145(5): 1189-1199, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30664811
4.
The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
BMC Cancer
; 16: 440, 2016 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27400708
5.
Amelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: reduced priming of proinflammatory effector CD4(+) T cells.
Am J Pathol
; 182(5): 1671-80, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23506849
6.
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Mol Cancer Ther
; 22(1): 89-101, 2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36343381
7.
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
J Immunother Cancer
; 10(11)2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36323431
8.
Erratum to: The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth.
BMC Cancer
; 16(1): 610, 2016 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27502070
9.
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy.
Expert Opin Biol Ther
; 21(12): 1635-1646, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043482
10.
The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis.
PLoS One
; 13(9): e0203228, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30183741
11.
A1M/α1-microglobulin is proteolytically activated by myeloperoxidase, binds its heme group and inhibits low density lipoprotein oxidation.
Front Physiol
; 6: 11, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25698971
12.
Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
J Immunother Cancer
; 3: 53, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26673090
13.
The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: leukocyte- and context-specific effects.
Int Immunopharmacol
; 18(2): 290-7, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24370393